Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER

BACKGROUND: Retrospective analyses of NSABP B20 and SWOG 8814 showed a large benefit of chemotherapy in patients with ER-positive tumors and high OncotypeDX Recurrence Score (RS≥31). However, it might be possible that both studies may be contaminated by non-luminal tumors, especially in high-risk RS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Sun, Z., Prat, A., Cheang, M.C.U., Gelber, R.D., Perou, C.M.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2015
Matèries:
breast tumor
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360145/
https://ncbi.nlm.nih.gov/pubmed/25355719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu493
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars